Doxorubicin is a classical but useful anti-tumour agent. It is used for the treatment of a variety of malignancies including solid tumours and leukaemia due to its broad spectrum anti-tumour activity. It also has well known toxic side effects that must be minimised for its successful use clinically. This book discusses intraperitoneal doxorubicin; preclinical characterisation of the drug-delivery device DCBeads for transarterial chemoembolisation of doxorubicin and nemorubicin; doxorubicin-induced cardiomyopathy; advanced therapies of doxorubicin by carrier of drug delivery system or combined food components; and prevention and management of cariotoxicity.
Preface; Intraperitoneal Doxorubicin:: Rationale, Pharmacokinetic Studies, & Clinical Results; Preclinical Characterization of the Drug-Delivery Device DCBeads for Transarterial Chemoembolization of Doxorubicin & Nemorubicin, a Methoxy-Morpholinyl Derivative; Doxorubicin-Induced Cardiomyopathy; Advanced Therapies of Doxorubicin by Carrier of Drug Delivery System or Combined Food Components; Prevention & Management of Cardiotoxicity, Nausea & Vomiting in Doxorubicin-Treated Breast Cancer Patients; Index.
Comments (0)
Your review appreciation cannot be sent
Report comment
Are you sure that you want to report this comment?
Report sent
Your report has been submitted and will be considered by a moderator.